Wound healing
Wound healing is where GHK-Cu’s preclinical case is broadest: rat and rabbit models mostly show faster wound closure,…
Moderate evidence, from one human trial and many animals
Wound healing is where GHK-Cu’s preclinical case is broadest: rat and rabbit models mostly show faster wound closure, though the record is not unanimous and one irradiated-tissue model found no benefit at all. It also has something most peptides lack, a randomized human trial, in diabetic foot ulcers.
This unit walks that diabetic-ulcer trial, the spread of animal models, the healing phases GHK-Cu is proposed to accelerate, and the honest tier: moderate and mostly preclinical, with one good human signal that has not been broadly replicated.
Key terms
The diabetic-ulcer trial
The standout human result is a multicenter, randomized, evaluator-blinded, placebo-controlled study of a GHK-Cu gel in diabetic foot ulcers. Treated ulcers reached far higher median area closure than vehicle. Note what the vehicle arm also received: every arm got intensive standard care, sharp debridement at study entry, standardized pressure-relieving footwear and patient education. The gel’s effect therefore sits on top of good wound care, not instead of it.
This is genuinely good evidence by peptide standards: randomized, controlled, with a clinically meaningful endpoint. The caution is that it is one older trial in a specific wound type, and it has not been confirmed by a large body of independent human studies.
AdvancedWhat the ulcer trial reports, and what it does not
It reports three things beyond the headline closure figures. The effect was larger in larger ulcers, a median of 89.2% against -10.3% for vehicle. There is a timing condition: treatment must commence immediately after the initial wound debridement for optimal enhancement. And infections were fewer, 7% against 34%. Now the gap. This course reaches the trial only as an abstract, so the number of patients, the arm sizes, the analysis population and the definition of the healing threshold are not readable and cannot be stated. A strong design whose sample size you cannot see is still a single older trial in one wound type.